239 related articles for article (PubMed ID: 11075938)
21. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
24. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
Stürmer M; Dauer B; Moesch M; Haberl A; Mueller A; Locher L; Knecht G; Hanke N; Doerr HW; Staszewski S
Antivir Ther; 2007; 12(1):25-30. PubMed ID: 17503744
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
[TBL] [Abstract][Full Text] [Related]
26. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
27. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
[TBL] [Abstract][Full Text] [Related]
28. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
29. Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
Goodall RL; Dunn DT; Nkurunziza P; Mugarura L; Pattery T; Munderi P; Kityo C; Gilks C; Kaleebu P; Pillay D; Gupta RK;
J Antimicrob Chemother; 2017 May; 72(5):1450-1455. PubMed ID: 28160504
[TBL] [Abstract][Full Text] [Related]
30. Salvage therapy studies.
Proj Inf Perspect; 1998 Sep; (25):7. PubMed ID: 11365850
[TBL] [Abstract][Full Text] [Related]
31. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
33. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
Vázquez-Rosales G; García Lerma JG; Yamamoto S; Switzer WM; Havlir D; Folks TM; Richman DD; Heneine W
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1191-200. PubMed ID: 10480632
[TBL] [Abstract][Full Text] [Related]
34. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
35. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
[TBL] [Abstract][Full Text] [Related]
36. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
[TBL] [Abstract][Full Text] [Related]
37. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P
J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
[TBL] [Abstract][Full Text] [Related]
38. Intensification of background antiretroviral therapy with abacavir during low-level failure may restore optimal suppression.
Degen O; van Lunzen J; Stellbrink HJ
Antivir Ther; 2000 Jun; 5(2):91-4. PubMed ID: 10971861
[TBL] [Abstract][Full Text] [Related]
39. Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment.
Pérez-Molina JA; Pérez Nr R; Miralles P; Cosín J; Padilla B; Berenguer J; Bouza E
HIV Clin Trials; 2001; 2(1):1-5. PubMed ID: 11590508
[TBL] [Abstract][Full Text] [Related]
40. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Ndembi N; Goodall RL; Dunn DT; McCormick A; Burke A; Lyagoba F; Munderi P; Katundu P; Kityo C; Robertson V; Yirrell DL; Walker AS; Gibb DM; Gilks CF; Kaleebu P; Pillay D;
J Infect Dis; 2010 Jan; 201(1):106-13. PubMed ID: 19938977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
